The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists ...

New research presented at the ACG Annual Meeting suggests that GLP-1RAs lower the risk of pancreatic cancer in patients with ...

Poor bowel preparation also led to repeat colonoscopies for 18.9% of current GLP-1RA users, compared to 11.1% of controls ...

opens new tab on Tuesday that most patients do not need to stop taking GLP-1 diabetes and weight-loss drugs before surgery, a ruling supported by a study presented this week at a medical meeting ...

Other GLP-1 drugs, such as exenatide (Byetta®) and liraglutide (Victoza®), have been linked with lean mass loss. Other diabetes drugs ... semaglutide topped a list of drug spending in the ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications ... Type 2 diabetes and types of cancer," the researchers noted ...

It's no secret that doctors are helping many people lose weight by prescribing GLP-1 medications like Ozempic, Wegovy, ...

Only 13 states currently allow Medicaid to cover GLP-1 agonist drugs for obesity treatment, highlighting a significant gap in ...

BOULDER, Colo., November 04, 2024--(BUSINESS WIRE)--PanTheryx ®, a global nutrition and biotechnology company, today announced the launch of Relesium™, a patented, all-natural supplement ...